The pattern recognition view organizes High Wave Candle recognition and supporting indicators around Lisata Therapeutics. The analysis highlights pattern recognition signals tied to momentum and continuation and frames technical signals with volatility and risk context.
The output start index for this execution was ten with a total number of output elements of fifty-one. The function generated a total of five valid pattern recognition events for the selected time horizon. The High-Wave Candle may signal Lisata Therapeutics market turn when observed in several bundles.
Lisata Therapeutics Technical Analysis Modules
Most technical analysis of Lisata Therapeutics help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Lisata from various momentum indicators to cycle indicators. When you analyze Lisata charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease andor promote the regeneration of damaged tissue. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. Lisata Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 27 people. Downside history and drawdown behavior provide context for risk expectations in Lisata Therapeutics. Past price movements indicate comparatively limited downside dispersion. Lisata Therapeutics has a market cap of 44.37 M, ROE of -72.17%.
Methodology
Unless otherwise specified, financial data for Lisata Therapeutics is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Lisata (USA Stocks:LSTA) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: The dataset for Lisata Therapeutics incorporates public filings and market reference sources and official institutional disclosures, including U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Some inputs may not update instantaneously. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Lisata Therapeutics is covered by 2 analysts. 1 analyst has submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Jefferies, Raymond James, Goldman Sachs, Bank of America Securities, Morgan Stanley, among others. Updates may occur throughout the day.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Lisata Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Lisata Therapeutics' short interest history, or implied volatility extrapolated from Lisata Therapeutics options trading.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment.
A structured review of Lisata Therapeutics often starts with core financial statements and trend context. Key ratios help frame profitability, efficiency, and growth context for Lisata Therapeutics Stock. Highlighted below are reports that provide context for Lisata Therapeutics Stock:
Lisata Therapeutics has a market cap of 44.37 M, operating margin of -18.77%, ROE of -72.17%. Correlation Analysis can help frame allocation decisions. The allocation includes a position in Lisata Therapeutics inside the allocation mix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
Explore our How to Trade Lisata Stock guide to learn how to trade Lisata Therapeutics effectively.Analysis related to Lisata Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Earnings Share
-2.13
Revenue Per Share
0.125
Return On Assets
-0.42
Return On Equity
-0.72
Market capitalization and book value offer complementary views of Lisata Therapeutics — the first driven by investor sentiment, the second by accounting standards. Lisata Therapeutics' market capitalization is 44.37 M. A P/B ratio of 2.55 indicates the market values Lisata Therapeutics above its accounting book value. Enterprise value stands at 22.45 M. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
Value and price for Lisata Therapeutics are related but not identical, and they can diverge across cycles. For Lisata Therapeutics, key inputs include a P/B ratio of 2.55, ROE of -72.17%, and revenue of 1000 K. By contrast, market price reflects the level where buyers and sellers transact.
